Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 8, 2008, Pages 793-800

  Nielsen, Vance G ^a,b   Kirklin, James K ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

Author keywords

Argatroban; Fibrinolysis; Heparin; Thrombelastography; Thrombin activatable fibrinolysis inhibitor; Tissue type plasminogen activator

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 13; HEPARIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBUS;

ANTICOAGULANTS; BLOOD COAGULATION; CARBOXYPEPTIDASE U; FACTOR XIII; FIBRINOLYSIS; HEPARIN; HUMANS; KAOLIN; KINETICS; PIPECOLIC ACIDS; THROMBELASTOGRAPHY; THROMBIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 57149108951     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328317f5aa     Document Type: Article

References (20)

1. Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban. II. Effects on fibrinolysis. J Biol Chem 2002; 227:50445-50449.
2. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14:557-562.
3. Semeraro F, Piro D, Rossiello MR, Ammollo T, Colucci M. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98:1208-1214.
4. Li N, He S, Blomback M, Hjemdahl P. Platelet activity, coagulation and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaprin. Arterioscler Thromb Vasc Biol 2007; 27:407-413.
5. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
6. Nielsen VG, Ellis IC. Thrombelastographic quantification of the contributions of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin to antifibrinolytic activity in human plasma. Blood Coagul Fibrinolysis 2007; 18:29-33.
7. Nielsen VG. Clot lifespan model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor. Blood Coagul Fibrinolysis 2008; 19:283-287.
8. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin and lepirudin do not decrease clot propagation and strength as effectively as heparin activated antithrombin in vitro. J Heart Lung Transplant 2006; 25:653-663.
9. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.
10. Taketomi T, Szlam F, Bader SO, Sheppard CA, Levy JH, Tanaka KA. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis 2008; 19:135-141.
11. 2-antiplasmin-plasmin interactions. Blood Coagul Fibrinolysis 2007; 18:647-656.
12. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275:20627-20631.
13. Ariens RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96:988-995.
14. Schneider M, Nagashima M, Knappe S, Zhao L, Morser J, Nesheim M. Amino acid residues in the P6-P′3 region of thrombin-activatable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem 2002; 277:9944-9951.
15. 2], acting on fibrin gels and γ-chain peptides. Biochem 1997; 36:995-1002.
16. Valnickova Z, Thogersen IB, Potempa J, Enghild JJ. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J Biol Chem 2007; 282:3066-3076.
17. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142:952-959.
18. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
19. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transaction bleeding time. Br J Pharmacol 1994; 113:1209-1214.
20. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1990; 33:1879-1885.